In Jacksonville and across the country, more men with low‑risk prostate cancer are deciding not to sprint into the operating room. Instead, they are choosing "active surveillance," a structured, watchful waiting approach that can help many men avoid long‑term sexual and urinary side effects without shortening life span for a large share of patients.
Nationwide uptick in active surveillance
Active surveillance has quickly shifted from niche strategy to mainstream option. A large analysis of the American Urological Association’s AQUA registry found that use of active surveillance for low‑risk prostate cancer rose from 26.5% in 2014 to 59.6% in 2021, according to JAMA Network Open. The study drew on more than 20,000 low‑risk cases from nearly 350 urology practices and found wide variation between providers in how often they offer surveillance instead of immediate surgery or radiation.
Randomized trial: survival similar at 15 years
One of the biggest reality checks came from the ProtecT randomized trial, which followed more than 1,600 men assigned to monitoring, surgery or radiotherapy. At 15 years, there was no statistically significant difference in prostate‑cancer–specific survival among the three groups, as reported by the New England Journal of Medicine. Men in the monitoring arm did have higher rates of progression and metastasis, but investigators noted that modern surveillance tools, including MRI and genomic risk tests, can help flag trouble early enough for curative treatment.
Large cohorts back up the safety signal
Big real‑world programs in North America have echoed those results. In one long follow‑up from a protocol‑driven active‑surveillance program, fewer than 1% of men on surveillance died of prostate cancer at 10 years, and under 2% developed metastases, according to Fred Hutch. Clinicians are quick to add that those low rates depend on choosing the right patients and sticking to a defined monitoring schedule.
How many men are affected?
All of this is playing out against a big demographic backdrop. More than 3.5 million U.S. men are living with a history of prostate cancer, and many will never die from the disease, according to the Cancer Treatment and Survivorship Statistics 2025. That large survivor population is a major reason experts are pressing for risk‑adapted care that can prevent the harms of unnecessary treatment.
Locally on the First Coast
On the First Coast, the trend has already hit the airwaves. A recent segment broke down the research and the rising use of surveillance; the clip is available via News4JAX. Physicians interviewed in the report underscored that active surveillance is not “doing nothing” but a deliberate medical plan that includes regular PSA tests, periodic MRI and biopsies when indicated.
Questions to bring to your doctor
If you or someone close to you has a new diagnosis of prostate cancer, it can help to head into the appointment with a short checklist. Ask about your risk group (including grade group, PSA level and stage), estimated life expectancy, and what a surveillance schedule would look like in practice. National guidance summarized by NCCN/UroToday emphasizes shared decision‑making and structured follow‑up for men who are good candidates for surveillance.
Bottom line: For carefully selected men with low‑risk prostate cancer, active surveillance often preserves life expectancy while limiting the lasting side effects of radical therapy. Talk with a urologist about whether surveillance matches your goals, and consider getting a second opinion if you are uncertain about the path you are being offered.
